MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO

Phase 2

Novartis AG (NVS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

NVSPhase 2$284.2B

MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO Phase 2 Est. Readout

MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO• Acute Myeloid Leukemia214

Apr 2027~Confirmed

CT.gov

00%

Competitive Landscape

3 competitors in Acute Myeloid Leukemia

SGENLintuzumab (SGN-33)

Phase 2

View Full Landscape

Drug Information

Target Indication

Acute Myeloid Leukemia

Clinical Trial

NCT04385290

Last updated: 8/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

lisinoprilPhase 3

Hypertension

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts